The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001
B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020
Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide Source: Eur Respir J 2012; 40: 152-160 Year: 2012
Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Specific monoclonal antibody to detect the C-terminal peptide of alpha1-antitrypsin: clinical importance Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
CD4+ T cell responses mediate protective immunity to influenza in the absence of protective antibody Source: Annual Congress 2010 - Mechanisms of respiratory infections Year: 2010
A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension Year: 2021
PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody Source: ERS Lung Science Conference 2021 Year: 2021
Anti-proteinase 3 antibodies prime CD14-dependent leukocyte activation Source: Eur Respir J 2002; 20: Suppl. 38, 228s Year: 2002
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
Dendritic cells stimulated by agonistic anti-CD40 mAb could elicit activation of lung cancer patients’ autologous cytotoxic T lymphocytes Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020 Year: 2021
Anti-IgE antibodies inhibit the expression of amphiregulin in mast cells and suppress remodeling Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012
Anti–fibrotic efficacy of Lck inhibitor via the suppression of TGF–ß production in regulatory T cells Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021
Differences in the response to treatment with monoclonal antibodies according to age Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy Source: Eur Respir J 2013; 41: 246-247 Year: 2013
A specific monoclonal antibody targeting C-36 peptide of alpha1-antitrypsin as a tool in respiratory research Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021